Misha Rosenbach
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Misha Rosenbach has a total of 438 co-authors. Here are the top co-authors by number of shared publications:
Karolyn A. Wanat
Medical College of Wisconsin
16 shared publicationsCaroline A. Nelson
Department of Dermatology, Yale School of Medicine, New Haven, Connecticut
7 shared publicationsMegan H. Noe
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
6 shared publicationsRobert G. Micheletti
Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
6 shared publications- Robert G. Micheletti
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
6 shared publications - Eva Rawlings Parker
Department of Dermatology and the Center for Biomedical Ethics and Society Vanderbilt University Medical Center Nashville Tennessee USA
5 shared publications
Latest Publications
- Open Access
- 11 June 2026
- Published by Elsevier in Journal of Investigative Dermatology
Artificial intelligence in dermatology: Clinical promise and environmental impact
- 11 June 2026
- Published by Elsevier in Journal of Investigative Dermatology
Open AccessArtificial intelligence in dermatology: Clinical promise and environmental impact
- Open Access
- 26 February 2026
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 46 (1)
Fatal Systemic Granulomatous Disease Associated with Vaccine-Derived Rubella Virus in AIOLOS-Associated Immunodeficiency
We present a case of disseminated granulomatous disease associated with live attenuated vaccine-derived rubella virus (VDRV) in an immunodeficient patient who subsequently developed fatal multi-organ failure, including neurological deficits, with VDRV detected in the cerebrospinal fluid. Posthumous genetic analysis found a heterozygous missense mutation in IKZF3 , a gene where haploinsufficiency is linked to immunodeficiency and immune dysregulation. Functional studies demonstrated that this mutation decreases AIOLOS protein stability and half-life, and family members carrying the same mutation exhibited decreased AIOLOS levels. This report underscores the importance of considering persistent rubella virus (RuV) infection in patients with cutaneous granulomatous lesions and highlights the need for comprehensive evaluation to uncover potential underlying immunodeficiencies, which could inform and optimize individualized treatment strategies.
- 26 February 2026
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 46 (1)
Open AccessFatal Systemic Granulomatous Disease Associated with Vaccine-Derived Rubella Virus in AIOLOS-Associated Immunodeficiency
We present a case of disseminated granulomatous disease associated with live attenuated vaccine-derived rubella virus (VDRV) in an immunodeficient patient who subsequently developed fatal multi-organ failure, including neurological deficits, with VDRV detected in the cerebrospinal fluid. Posthumous genetic analysis found a heterozygous missense mutation in IKZF3 , a gene where haploinsufficiency is linked to immunodeficiency and immune dysregulation. Functional studies demonstrated that this mutation decreases AIOLOS protein stability and half-life, and family members carrying the same mutation exhibited decreased AIOLOS levels. This report underscores the importance of considering persistent rubella virus (RuV) infection in patients with cutaneous granulomatous lesions and highlights the need for comprehensive evaluation to uncover potential underlying immunodeficiencies, which could inform and optimize individualized treatment strategies.
- 7 November 2025
- Published by Elsevier in Dermatologic Clinics
- Vol. 44 (1)
Climate Change and Dermatology: A Review and Update for 2026 and Beyond
- 7 November 2025
- Published by Elsevier in Dermatologic Clinics
- Vol. 44 (1)
Climate Change and Dermatology: A Review and Update for 2026 and Beyond
- Open Access
- 26 September 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (1) , 161-163
Long-term morbidity and quality of life in survivors of Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum
This is one of the largest long-term studies following an SJS/TEN reaction that reports long-term survey-based sequelae and adds to the understanding of SJS/TEN as a condition with chronic complications long beyond the acute reaction. We report significant long-term life impacts among survivors of SJS/TEN in the USA. Additional follow-up and long-term care of this patient population is of the utmost importance.
- 26 September 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (1) , 161-163
Open AccessLong-term morbidity and quality of life in survivors of Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum
This is one of the largest long-term studies following an SJS/TEN reaction that reports long-term survey-based sequelae and adds to the understanding of SJS/TEN as a condition with chronic complications long beyond the acute reaction. We report significant long-term life impacts among survivors of SJS/TEN in the USA. Additional follow-up and long-term care of this patient population is of the utmost importance.
- Open Access
- 19 August 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (20)
SAA1/FPR2 signaling between keratinocytes and neutrophils sustains chronic inflammation in Sweet syndrome
Sweet syndrome (also known as acute febrile neutrophilic dermatosis) is a rare inflammatory skin disorder characterized by erythematous plaques with a dense dermal neutrophilic infiltrate. The first-line therapy remains oral corticosteroids, which suppresses inflammation nonspecifically. Although neutrophils are typically short-lived, how they persist in Sweet syndrome skin and contribute to disease pathogenesis remains unclear. Here, we identify a previously unrecognized population of antigen-presenting cell–like (APC-like) neutrophils expressing MHC class II genes that are uniquely present in Sweet syndrome skin but absent in healthy tissue and the circulation. Keratinocytes extended neutrophil lifespan 10-fold in coculture experiments and drove the emergence of an APC-like phenotype in approximately 30% of neutrophils, mirroring observations in patients’ lesions. Mechanistically, keratinocyte-derived serum amyloid A1 (SAA1) signals through the formyl peptide receptor 2 (FPR2) on neutrophils to promote their survival. These long-lived neutrophils actively orchestrate local immune responses by recruiting T cells and inducing cytokine production. Strikingly, dual blockade of SAA1/FPR2 signaling restores neutrophil turnover to baseline levels, with efficacy comparable to high-dose corticosteroids. These findings uncover a keratinocyte/neutrophil/T cell axis that sustains chronic inflammation in Sweet syndrome and highlight the SAA1/FPR2 pathway as a promising target for precision therapy.
- 19 August 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (20)
Open AccessSAA1/FPR2 signaling between keratinocytes and neutrophils sustains chronic inflammation in Sweet syndrome
Sweet syndrome (also known as acute febrile neutrophilic dermatosis) is a rare inflammatory skin disorder characterized by erythematous plaques with a dense dermal neutrophilic infiltrate. The first-line therapy remains oral corticosteroids, which suppresses inflammation nonspecifically. Although neutrophils are typically short-lived, how they persist in Sweet syndrome skin and contribute to disease pathogenesis remains unclear. Here, we identify a previously unrecognized population of antigen-presenting cell–like (APC-like) neutrophils expressing MHC class II genes that are uniquely present in Sweet syndrome skin but absent in healthy tissue and the circulation. Keratinocytes extended neutrophil lifespan 10-fold in coculture experiments and drove the emergence of an APC-like phenotype in approximately 30% of neutrophils, mirroring observations in patients’ lesions. Mechanistically, keratinocyte-derived serum amyloid A1 (SAA1) signals through the formyl peptide receptor 2 (FPR2) on neutrophils to promote their survival. These long-lived neutrophils actively orchestrate local immune responses by recruiting T cells and inducing cytokine production. Strikingly, dual blockade of SAA1/FPR2 signaling restores neutrophil turnover to baseline levels, with efficacy comparable to high-dose corticosteroids. These findings uncover a keratinocyte/neutrophil/T cell axis that sustains chronic inflammation in Sweet syndrome and highlight the SAA1/FPR2 pathway as a promising target for precision therapy.
- Open Access
- 19 June 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 64 (12) , 2195-2197
Prescribing for the Planet: Integrating Life Cycle Analyses Into Therapeutic Decision‐Making in Dermatology
- 19 June 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 64 (12) , 2195-2197
Open AccessPrescribing for the Planet: Integrating Life Cycle Analyses Into Therapeutic Decision‐Making in Dermatology
- Open Access
- 30 May 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 62, 12-14
Late-season Vibrio vulnificus infection leading to purpura fulminans
- 30 May 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 62, 12-14
Open AccessLate-season Vibrio vulnificus infection leading to purpura fulminans
- Open Access
- 11 April 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 61, 154-156
Granuloma annulare treated with certolizumab following the development of antidrug antibodies to adalimumab
- 11 April 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 61, 154-156
Open AccessGranuloma annulare treated with certolizumab following the development of antidrug antibodies to adalimumab
- Open Access
- 31 March 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 65, 112-115
Cytomegalovirus anogenital ulcers in an immunosuppressed patient
- 31 March 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 65, 112-115
Open AccessCytomegalovirus anogenital ulcers in an immunosuppressed patient